For research use only. Not for therapeutic Use.
Hypericin-d2, a premium pharmaceutical research compound designed for advanced studies in photodynamic therapy and antidepressant research. As a deuterated analog of Hypericin, it offers enhanced stability and improved pharmacokinetic properties. Hypericin-d2 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for depression and certain types of cancer. Trusted by leading laboratories, Hypericin-d2 is your go-to solution for cutting-edge photodynamic and antidepressant research. Unlock new possibilities in treatment with Hypericin-d2, where innovation meets reliability.
| Catalog Number | S000237 |
| Molecular Formula | C30H14D2O8 |
| Purity | ≥95% |
| Target | Anti-infection |
| IUPAC Name | 12,17-dideuterio-9,11,13,16,18,20-hexahydroxy-5,24-dimethyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,8,10,12,14(28),15(27),16,18,20,23-tridecaene-7,22-dione |
| InChI | InChI=1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,33-38H,1-2H3/i5D,6D |
| InChIKey | YDOIFHVUBCIUHF-KCZCTXNHSA-N |
| SMILES | [2H]C1=C(C2=C3C4=C5C(=C6C(=CC(=O)C7=C(C8=C(C(=C(C2=C8C4=C67)O)[2H])O)O)C)C(=CC(=O)C5=C(C3=C1O)O)C)O |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Agostinis P et al. Hypericin in cancer treatment: more light on the way. [3]. Lenard J et al. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses usinghypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):158-62. [4]. Hwang MS et al. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin. |
